Scarica l'app Stockscreener
16.30
3.62%
0.57
Precedente Chiudi:
$15.73
Aprire:
$15.92
Volume 24 ore:
845.04K
Relative Volume:
0.94
Capitalizzazione di mercato:
$962.94M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-4.4173
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
+13.51%
1M Prestazione:
+32.20%
6M Prestazione:
+135.89%
1 anno Prestazione:
+100.49%
Intervallo 1D:
$15.54
$16.44
Intervallo di 1 settimana:
$13.67
$16.74
Portata 52W:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
16.30 | 929.27M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Iniziato | Citigroup | Buy |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics executives to join major healthcare conference fireside chats - Traders Union
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $25,169.20 in Stock - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Cullinan Therapeutics (CGEM) CSO sells 1,780 shares in Rule 10b5-1 trade - Stock Titan
CGEM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,752 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 3,601 Shares of Stock - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $66,301.54 in Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) CEO Nadim Ahmed Sells 13,515 Shares - MarketBeat
Cullinan Therapeutics (CGEM) CSO sells 5,353 shares under 10b5-1 plan - Stock Titan
Cullinan Therapeutics (CGEM) CMO sells shares to cover RSU tax bill - Stock Titan
[Form 4] Cullinan Therapeutics, Inc. Insider Trading Activity - Stock Titan
Jennifer Michaelson sells shares under 10b5-1 (CGEM) - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month HighWhat's Next? - MarketBeat
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jeffrey Alan Jones Sells 4,982 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells 4,398 Shares of Stock - MarketBeat
Cullinan Therapeutics (CGEM) CMO sells 4,982 shares for RSU tax obligations - Stock Titan
Cullinan Therapeutics (CGEM) CSO exercises options and sells 11,742 shares - Stock Titan
Cullinan Therapeutics (CGEM) CLO sells 3,742 shares to cover tax - Stock Titan
Cullinan Therapeutics (CGEM) CEO sells shares to cover RSU tax bill - Stock Titan
Cullinan Therapeutics (CGEM) CFO sells shares to cover RSU tax bill - Stock Titan
CGEM (NASDAQ: CGEM) Form 144 shows 1,752-share proposed resale; insider sales listed - Stock Titan
Cullinan Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Is Cullinan Therapeutics Inc. benefiting from innovation trendsCEO Change & Detailed Earnings Play Strategies - mfd.ru
Cullinan Therapeutics (NASDAQ:CGEM) Cut to Hold at Zacks Research - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Zacks Research - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: A Biotech With 120% Upside Potential - DirectorsTalk Interviews
Will Cullinan Therapeutics Inc. stock recover faster than peersJuly 2025 PreEarnings & Smart Money Movement Alerts - mfd.ru
What is the long term forecast for Cullinan Therapeutics Inc. stockJuly 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
What is Cullinan Therapeutics Inc.’s valuation compared to sectorJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - mfd.ru
Jennifer Michaelson proposes sale of 8,000 shares | CGEM SEC FilingForm 144 - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Research Coverage Started at Citigroup - Defense World
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighTime to Buy? - MarketBeat
CGEM: 2026 will bring major clinical and regulatory milestones across oncology and autoimmune programs - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - The Globe and Mail
Cullinan leaders join Citi virtual oncology fireside chat on Feb. 19 - Stock Titan
Citigroup Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Citigroup Initiates Buy Coverage on CGEM with $33 Target | CGEM Stock News - GuruFocus
Citigroup Initiates Cullinan Therapeutics at Buy With $33 Price Target - marketscreener.com
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):